Literature DB >> 17888042

Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison.

Madelon N M van der Aa1, Ewout W Steyerberg, E Fatma Sen, Ellen C Zwarthoff, Wim J Kirkels, Theo H van der Kwast, Marie-Louise Essink-Bot.   

Abstract

OBJECTIVE: To compare, in patients with non-muscle-invasive low-grade (pTa/pT1, G1/G2) urothelial cell carcinoma of the urinary bladder, the perceived burden of flexible cystoscopy or surveillance by microsatellite analysis (MA) in voided urine, as such patients are normally recommended to adhere to regular cysto-urethroscopic surveillance (CUS). PATIENTS AND METHODS: In all, 220 participants of a randomized trial comparing CUS and surveillance by MA were asked to complete questionnaires 1 week after cystoscopy or urine sample collection. We assessed the discomfort and pain reported during CUS, experiences with MA, and physical symptoms, medical consumption and general functioning in the week after CUS/urine sampling.
RESULTS: We analysed data from 732 questionnaires (197 patients) completed after CUS and 184 (67 patients) after collecting urine. The introduction of the cystoscope was reported to cause discomfort in 39% and pain in 35% of the responses to the questionnaires; the waiting time for the results of MA was reported as burdensome in 19%. Painful micturition was significantly more frequent in the week after CUS than after MA (30% and 12%, respectively). The frequency of fever (1% and 2%) and haematuria (7% and 6%) was similar in both groups. Older patients reported significantly less pain and discomfort from cystoscopy, and this was not related to having more previous cystoscopies.
CONCLUSION: CUS caused pain and discomfort in about a third of patients. The burden of MA appeared fully attributable to the waiting time for the test result. The present results are a further motivation in the search for less invasive surveillance tests.

Entities:  

Mesh:

Year:  2007        PMID: 17888042     DOI: 10.1111/j.1464-410X.2007.07224.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  28 in total

1.  Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer.

Authors:  Willemien Beukers; Raju Kandimalla; Roy G Masius; Marcel Vermeij; Ries Kranse; Geert Jlh van Leenders; Ellen C Zwarthoff
Journal:  Mod Pathol       Date:  2014-11-14       Impact factor: 7.842

2.  Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives.

Authors:  Rashid K Sayyid; Abdallah K Sayyid; Zachary Klaassen; Karen Hersey; Hanan Goldberg; Nathan Perlis; Ardalanejaz Ahmad; Ricardo Leao; Thenappan Chandrasekar; Kamel Fadaak; Rabii Madi; Martha K Terris; Antonio Finelli; Robert J Hamilton; Girish S Kulkarni; Alexandre R Zlotta; Neil E Fleshner
Journal:  Can Urol Assoc J       Date:  2018-02-06       Impact factor: 1.862

3.  The value of molecular markers in classification and prediction of progression in non-muscle-invasive bladder cancer.

Authors:  Chin-Chen Pan
Journal:  Transl Androl Urol       Date:  2018-08

4.  Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine.

Authors:  Yasushi Nakai; Toshiyuki Ozawa; Fumiko Mizuno; Sayuri Onishi; Takuya Owari; Syunta Hori; Yosuke Morizawa; Yosihiro Tatsumi; Makito Miyake; Nobumichi Tanaka; Daisuke Tsuruta; Kiyohide Fujimoto
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-19       Impact factor: 4.553

5.  Quantitation of rare circulating tumor cells by folate receptor α ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance.

Authors:  Fuming Qi; Yuchen Liu; Rongchang Zhao; Xiangjun Zou; Lei Zhang; Jiaqiang Li; Yongqiang Wang; Feiyang Li; Xiaowen Zou; Ye Xia; Xuliang Wang; Li Xing; Cailing Li; Jingxiao Lu; Junlong Tang; Fangjian Zhou; Chunxiao Liu; Yaoting Gui; Zhiming Cai; Xiaojuan Sun
Journal:  Tumour Biol       Date:  2014-04-27

6.  Expression of miRNA-630 in bladder urothelial carcinoma and its clinical significance.

Authors:  Zhi-Yu Wang; Wei Zhang; Jin-Jian Yang; Dong-Kui Song; Jin-Xing Wei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

Review 7.  Bladder cancer.

Authors:  David J Gallagher; Matthew I Milowsky
Journal:  Curr Treat Options Oncol       Date:  2009-08

8.  In-depth investigation of the molecular pathogenesis of bladder cancer in a unique 26-year old patient with extensive multifocal disease: a case report.

Authors:  Tahlita C M Zuiverloon; Cheno S Abas; Kirstin A van der Keur; Marcel Vermeij; Stephen S Tjin; Angela G van Tilborg; Martijn Busstra; Ellen C Zwarthoff
Journal:  BMC Urol       Date:  2010-02-26       Impact factor: 2.264

9.  FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Authors:  Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo H van der Kwast; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

10.  Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review.

Authors:  Claudia Rutherford; Manish I Patel; Margaret-Ann Tait; David P Smith; Daniel S J Costa; Shomik Sengupta; Madeleine T King
Journal:  Qual Life Res       Date:  2020-09-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.